Does Amgen (AMGN) Change The Oncology Case With This Phase 3 Survival Win?

• Amgen (NasdaqGS:AMGN) reported Phase 3 DeLLphi-305 results for IMDELLTRA in first-line maintenance extensive stage small cell lung cancer.
• The study is described as the first Phase 3 trial to show an overall survival benefit for a BiTE therapy in this setting.
• Management positioned the positive DeLLphi-305 outcome as a key milestone for Amgen's oncology franchise and treatment options in small cell lung cancer.
• The DeLLphi-305 survival data for IMDELLTRA adds fresh context to the broader picture emerging from Amgen's fundamentals and risk profile. Check out 1 warning sign that Amgen investors should know about.

This kind of small cell lung cancer treatment progress is only one angle on oncology exposure, so it is worth comparing with other under-the-radar quality stocks exposed to similar themes through our screener containing 16 high quality undiscovered gems.

Amgen is a large US biotech group with a US$206.8b market cap that focuses on discovering, developing, manufacturing, and delivering human therapeutics worldwide, so a late stage asset like IMDELLTRA fits directly into its core drug development engine in oncology.

4 things going right for Amgen that this headline doesn't cover.

IMDELLTRA’s survival win reinforces Amgen’s oncology Narrative, but commercial execution is still the question

For Amgen, the DeLLphi-305 result strengthens the part of its Narrative that leans on high margin, targeted therapies to support long term revenue and earnings. A first BiTE therapy showing an overall survival benefit in first line extensive stage small cell lung cancer ties directly into the late stage oncology pipeline that analysts see as a driver alongside cardiometabolic and biosimilar opportunities. It also fits the theme of expanding into serious chronic and age related diseases, one of the key catalysts in the current analyst view. What this update does not settle is how much IMDELLTRA can practically contribute once pricing pressure, biosimilar competition and safety management costs are layered in.

See how these catalysts shape Amgen's path to a $372 fair value.

The next real proof point is the detailed DeLLphi-305 data presentation at the upcoming international medical congress and any feedback from regulators that follows. That is where investors will be able to gauge how clinicians view the survival, progression free survival and safety profile alongside monitoring requirements, and what this could mean for treatment uptake and eventual revenue contribution inside Amgen’s broader oncology franchise.

Add Amgen to your Watchlist and get alerts as these catalysts play out.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com